A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury.

A double-blind, placebo-controlled, randomized, multi-centre, phase III study of MLC901 (NeuroAiDTMII) for the treatment of cognitive impairment after mild traumatic brain injury.

Show other versions (1)

<h4>Introduction</h4>About half of the world population will suffer from a traumatic brain injury (TBI) during their lifetime, of which about 90% of cases are mild TBI. Although up to 40% of adults with mild TBI experience persistent functional deficits, there is no proven-effective trea...

Full description

Saved in:
Bibliographic Details
Main Authors: Pavel I Pilipenko, Anna A Ivanova, Yulia V Kotsiubinskaya, Vera N Grigoryeva, Alexey Y Khrulev, Anatoly V Skorokhodov, Maxim M Gavrik, Nona N Mkrtchan, Marek Majdan, Peter Valkovic, Daria Rabarova, Suzanne Barker-Collo, Kelly Jones, Valery L Feigin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2025-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0310229
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items